Zhengrong Deng

Zhengrong Deng

Auto-generated profile, based on publicly available information

Zhengrong Deng

West China Second University Hospital 2 Department of Obstetrics and Gynecology, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province and State Key Laboratory of Biotherapy Sichuan University and Collaborative Innovation Center, Chengdu, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2025 in Cancer Discovery
Verified
Journal Article
Closed access
QXQin Xu
Qin Xu
ZDZhengrong Deng
Zhengrong Deng
JLJing Liu
Jing Liu
YZYanhong Zhuo
Yanhong Zhuo
FZFei Zhu
Fei Zhu
SZShengtao Zhou
Shengtao Zhou
The standard of care for advanced cervical cancer includes chemotherapy, antiangiogenic, and/or immune checkpoint blockade regimens. Although effective, it leads to pleiotropic side effects. Deescalation chemotherapy together with immunotargeted therapies has been proven effective and less toxic in other cancers. In this study, we conducted a multicenter, single-arm, phase II study of first-line deescalated platinum-based chemotherapy plus anlotinib and penpulimab, followed by maintenance therapy solely with anlotinib and penpulimab in patients with PD-L1–positive, persistent, recurrent, or metastatic cervical cancer. Of 32 efficacy-evaluable patients, 30 (93.8%, 95% confidence interval, 79.2%–99.2%) had an investigator-confirmed objective response. Single-nucleus RNA sequencing implied enhanced chemotaxis and proliferative activity of tumor-infiltrating T cells, and activated germinal center B cells portended optimal treatment response. Patients with a high tertiary lymphoid structure-to-tumor area ratio exhibited better survival. Our findings lay the groundwork for the feasibility of first-line de-escalated chemotherapy plus anlotinib and penpulimab in patients with metastatic, persistent, or recurrent cervical cancer. Significance: We recruited 34 patients with advanced cervical cancer receiving two cycles of platinum-based chemotherapy plus anlotinib and penpulimab, followed by maintenance therapy solely with anlotinib and penpulimab, and showed safety and efficacy of this deescalation regimen. This work highlights the potential for personalized treatment strategies and feasibility of reduced-toxicity regimens.

2 March 2026
Verified
Other
Open access
PDF file
QXQin Xu
Qin Xu
ZDZhengrong Deng
Zhengrong Deng
JLJing Liu
Jing Liu
YZYanhong Zhuo
Yanhong Zhuo
FZFei Zhu
Fei Zhu
SZShengtao Zhou
Shengtao Zhou
Fig. S5. Transcriptional signatures and TMB levels in tumor samples from patients dichotomized by the mPFS.

2 March 2026
Verified
Other
Open access
PDF file
QXQin Xu
Qin Xu
ZDZhengrong Deng
Zhengrong Deng
JLJing Liu
Jing Liu
YZYanhong Zhuo
Yanhong Zhuo
FZFei Zhu
Fei Zhu
SZShengtao Zhou
Shengtao Zhou
Fig. S7. Immune profiling of CD4⁺ cells from patients stratified by CR versus PR and by mPFS.

2 March 2026
Verified
Other
Open access
PDF file
QXQin Xu
Qin Xu
ZDZhengrong Deng
Zhengrong Deng
JLJing Liu
Jing Liu
YZYanhong Zhuo
Yanhong Zhuo
FZFei Zhu
Fei Zhu
SZShengtao Zhou
Shengtao Zhou
Fig. S8. Peripheral immune landscape dynamics across treatment time points and response groups.

2 March 2026
Verified
Other
Open access
PDF file
QXQin Xu
Qin Xu
ZDZhengrong Deng
Zhengrong Deng
JLJing Liu
Jing Liu
YZYanhong Zhuo
Yanhong Zhuo
FZFei Zhu
Fei Zhu
SZShengtao Zhou
Shengtao Zhou
Fig. S12. Multiplex immunofluorescence of TLS, tumor cells, and the FN1-CD44 ligand–receptor pair.

2 March 2026
Verified
Other
Open access
PDF file
QXQin Xu
Qin Xu
ZDZhengrong Deng
Zhengrong Deng
JLJing Liu
Jing Liu
YZYanhong Zhuo
Yanhong Zhuo
FZFei Zhu
Fei Zhu
SZShengtao Zhou
Shengtao Zhou
Fig. S10. Immune profiling of GC B-BCL6 cells from patients stratified by the mPFS.